A Nature Review has been issued, covering the
gut microbiota’s role in colorectal cancer.
According to new experimental evidence from Jun Yu’s
group at The University of Hong Kong, the gut microbiota is a key cog in the
formation and progression of colorectal cancer. Gut bacteria play a role in
preventing adverse effects of treatment too. Clinical data demonstrated that
clear changes in the number of specific bacteria are detected in patients and
can even serve as a biomarker for disease screening to help to inform a
patient’s response to a certain treatment. It’s clear that modulation of the
gut microbiota is an excellent strategy to enhance treatment efficacy and
reduce adverse effects of colorectal cancer therapies.
Posted by Dr. Tim Sandle,
Pharmaceutical Microbiology
According to new experimental evidence from Jun Yu’s
group at The University of Hong Kong, the gut microbiota is a key cog in the
formation and progression of colorectal cancer. Gut bacteria play a role in
preventing adverse effects of treatment too. Clinical data demonstrated that
clear changes in the number of specific bacteria are detected in patients and
can even serve as a biomarker for disease screening to help to inform a
patient’s response to a certain treatment. It’s clear that modulation of the
gut microbiota is an excellent strategy to enhance treatment efficacy and
reduce adverse effects of colorectal cancer therapies.
No comments:
Post a comment
Pharmaceutical Microbiology Resources